Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02947984 · ClinicalTrials.gov registry record · Phase 3
Proton/Photon Rt - Benign Meningiomas(P92-13)
A Phase 3 study of Benign Meningioma, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 3
- Development phase
- 44
- Enrollment target
- 1
- Study location
NCT02947984 is a Phase 3 study of Benign Meningioma that has completed, run by Massachusetts General Hospital. The registered enrollment target is 44 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02947984, a Phase 3 study of Benign Meningioma, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 44 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the best radiation dose for participants with meningioma that has grown back after previous surgery, or which the surgeon has been unable to remove completely. This research study is designed to determine whether a higher dose of radiation will decrease the likelihood that the tumor will grow back, compared to the probability of re-growth that occurs after standard radiation doses.
Conditions Studied
Interventions
- RADIATION Standard Treatment
- RADIATION Higher Dose
Study Locations (1)
Massachusetts
- Massachusetts General Hosital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 1999-03 |
| Est. Completion | 2016-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02947984
The ClinicalTrials.gov registry entry for NCT02947984 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Benign Meningioma appearing as the primary indexed condition, and to 2 interventions - of which Standard Treatment is the first listed.
NCT02947984 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02947984 about?
NCT02947984 is a clinical study titled "Proton/Photon Rt - Benign Meningiomas(P92-13)". The purpose of this study is to determine the best radiation dose for participants with meningioma that has grown back after previous surgery, or which the surgeon has been unable to remove completely. This research study is designed to determine whether a higher dose of radiation will decrease the ...
What is the current status of trial NCT02947984?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 44 participants. The study started on 1999-03. Estimated completion is 2016-09.
What conditions does trial NCT02947984 study?
This clinical trial studies the following conditions: Benign Meningioma.
What interventions are being tested in trial NCT02947984?
The interventions under investigation include: Standard Treatment (RADIATION), Higher Dose (RADIATION).
Who is sponsoring clinical trial NCT02947984?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02947984 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.